Tonix Pharmaceuticals Holding Corp.
RECOMBINANT POXVIRUS BASED VACCINE AGAINST SARS-CoV-2 VIRUS
Last updated:
Abstract:
The invention relates in various aspects to a recombinant poxvirus comprising a nucleic acid encoding a SARS-CoV-2 virus protein, methods for producing such viruses and the use of such viruses. The recombinant poxviruses are well suited, among others, as protective virus vaccines against SARS-CoV-2 virus.
Status:
Application
Type:
Utility
Filling date:
26 Feb 2021
Issue date:
26 Aug 2021